

When is acute persistent cough in school-age children and adults whooping cough?

A prospective case series study

Abstract

Background

Pertussis is a vaccine modified disease in most age groups and hence subtle in its presentation. Current diagnostic approaches require relatively invasive sampling.

Aim

To determine the incidence of *B. pertussis* infection among people aged 5–49 years identified in primary care with acute persistent cough using an oral fluid based diagnostic test.

Design and setting

Active surveillance of acute persistent cough of 2 weeks duration or greater was established in Auckland, New Zealand from May to October 2011. The 15 participating primary care practices provided care for a socioeconomically diverse population.

Method

Recent *B. pertussis* infection was determined by measurement of IgG antibodies to pertussis toxin (PT) in an oral fluid sample. An IgG antibody titre to PT of ≥ 70 arbitrary units defined recent infection. Participants reported symptoms at presentation and kept a cough diary.

Results

A total of 226 participants were enrolled: 70 (31%) were children (5–16 years) and 156 (69%) were adults (17–49 years). Oral fluid samples were obtained from 225 participants. Ten per cent (23/225) had recent *B. pertussis* infection including a larger proportion of children than adults (17% versus 7%, $P = 0.003$). Neither cough duration nor any individual symptom discriminated between those with and without recent *B. pertussis* infection.

Conclusion

Pertussis is a frequent cause of acute persistent cough presenting to primary care. Clinical differentiation of pertussis from other causes of acute persistent cough is difficult. An oral fluid based diagnostic test, which is less invasive than other diagnostic approaches, has high acceptability in primary care.

Keywords

Bordetella pertussis; cough, general practice; signs and symptoms, respiratory; whooping cough.

INTRODUCTION

Pertussis is a highly contagious infection. Household contacts (people visiting or living in the home), are the most frequent source of infection for infants hospitalised with pertussis.¹ Pertussis can be difficult to distinguish from other coughing illnesses, and this may be confounded in individuals who have previously received pertussis vaccination and have a more subtle presentation.

Studies of adolescents and adults with prolonged cough illnesses from Asia, Australia, Europe, and North America have shown that *B. pertussis* infection is a frequent cause of such illnesses.² The ability to demonstrate recent infection with *B. pertussis* in these age groups was made possible by development of sensitive and specific ELISA assays that measure antibodies to *B. pertussis* antigens in sera. Initially paired serum samples were necessary but more recently, diagnosis based upon measurement of IgG antibodies to pertussis toxin (PT) on a single serum sample has become possible.³ However, requiring a blood sample for diagnosis reduces the acceptability of such testing, particularly for children.

Acute persistent cough is a common presentation in general practice with an extensive differential diagnosis. Diagnostic uncertainty potentially leads to excessive investigation and management. Being able

to establish the presence of *B. pertussis* infection is therefore not only important from an infection control perspective but also reduces unnecessary further intervention. Ability to achieve this in primary care has been restricted by the limited availability of diagnostic tests with adequate sensitivity and specificity and with a simple and non-invasive collection of the biological sample.

The aim of this study was to estimate the proportion of school-aged children and adults under 50 years of age identified in general practice with acute persistent cough who had recent infection with *B. pertussis* and to determine whether there are symptoms that predict *B. pertussis* infection. The study used an oral fluid-based assay as the diagnostic test for *B. pertussis* infection, and to demonstrate the applicability of this test to the primary care setting.

METHOD

Study design and setting

The study completed a prospective case series of school-age children (aged 5–16 years) and adults (17–49 years) identified in primary care in Auckland, New Zealand, with an acute persistent cough of 2 weeks duration or greater between May and October 2011. Cases were identified from a convenience sample of general practices, selecting for socioeconomic

K Philipson, MBChB, Master in Public Health student, Department of General Practice & Primary Health Care; **F Goodyear-Smith**, MD, FRNZCGP, GP and professor in the Department of General Practice & Primary Health Care; **CC Grant**, PhD, FACP, paediatrician and associate professor in paediatrics; **A Chong**, BBus, RGN, research nurse and project manager; **N Turner**, MPH, FRNZCGP, GP and director, Immunisation Advisory Centre; **J Stewart**, MSc, senior research fellow and biostatistician, Faculty of Medical & Health Sciences, University of Auckland, Auckland, New Zealand.

Address for correspondence

Felicity Goodyear-Smith, Department of General Practice & Primary Health Care, University of Auckland, PB 92019 Auckland, New Zealand.

E-mail: f.goodyear-smith@auckland.ac.nz

Submitted: 19 January 2013; **Editor's response:**

28 February 2013; **final acceptance:**

25 March 2013.

©British Journal of General Practice

This is the full-length article (published online 29 Jul 2013) of an abridged version published in print. Cite this article as: **Br J Gen Pract 2013;**

DOI: 10.3399/bjgp13X670705

How this fits in

Pertussis is a recognised cause of acute persistent cough presenting to primary care in first world countries. Laboratory diagnosis of pertussis in the primary care setting is difficult with the clinical presentation of pertussis to primary care in populations that have received booster doses of acellular pertussis vaccine not well defined. In this study it is demonstrated that an oral fluid based assay that measures antibodies to pertussis toxin is an ideal test for the primary care setting. In New Zealand, where pertussis vaccine boosters are given at ages 4 and 11 years, recent *Bordetella pertussis* infection is evident in 17% of children 5–16 years old and 7% of adults 17–49 years old identified in primary care with acute persistent cough. Neither cough duration nor any individual presenting symptom discriminate those with pertussis from those with acute persistent cough due to other causes.

diversity and pragmatic factors including willingness to engage in primary care research.

Participants

The study sought to enrol 200 children and adults aged 5–49 years with an acute persistent cough. The cut-off age of 49 years was a pragmatic decision to enable comparison with a similar study being conducted by the study's Oxford colleagues. The study excluded those with an underlying medical condition which may cause a persistent cough (for example, bronchiectasis, cardiac failure) or who were immune-compromised. A number of

studies have found an incidence of pertussis in primary care and emergency department settings in the range 10–30%.^{4–9} A sample size of 200 was sufficient to estimate the incidence of *B. pertussis* infection with 95% confidence limits of $\pm 4\%$ if the true incidence was 10%, and $\pm 6\%$ if the true incidence was 30%.

Recruitment

Potential participants were invited to participate by members of the general practice team (GP, practice nurse, administration staff). Details of eligible patients who agreed to participate were sent by practice staff to the research nurse, who then recruited participants for the study.

During a face-to-face interview written informed consent was obtained and participants completed a questionnaire, self-administered collection of an oral fluid (Oracol) swab and agreed to complete a cough diary. Collection of the oral fluid sample involved rubbing the applicator sponge over the gums for 1 minute, hence is a sample of gingival fluid rather than saliva. A daily cough diary was kept for 14 days, with a further weekly diary for 12 weeks if their cough persisted, or until the cough stopped.

Diagnosis of *B. pertussis* infection

Recent *B. pertussis* infection was determined by measurement of the concentration of IgG antibodies to pertussis toxin (PT) in the oral fluid sample. While previously a significant increase in paired sera samples was considered necessary for diagnosis, studies testing serum specimens vaccinees and pertussis patients have found high IgG levels to be very rare in the general population.¹⁰ IgG antibodies appear in the early weeks after infection, peak within a few months, and then decline. A study using matched serum and oral fluid samples in children whose serum anti-PT titre had already been determined, found that the oral fluid assay detected seropositive subjects with a sensitivity of 80% and a specificity of 97%.¹¹ A single oral fluid assay is therefore a valid surrogate for a serum ELISA.

Currently this assay is only measurable at the Respiratory and Systemic Infection Laboratory (RSIL), England. To maintain sample integrity samples were kept chilled using ice packs and/or refrigeration. LabPLUS pre-processed samples, eluted from the Oracol swab (Figure 1) using a transport medium. Once eluted the contents were split into two microtubes, one as a master and one as a backup and

Figure 1. Oracol swab.




Figure 2. Summary of patient enrolment and data collection.




Table 1. Characteristics of the 226 enrolled participants

Characteristic	n (%)
Age, years	
5–16	70 (31)
17–49	156 (69)
Female sex	143 (63)
Ethnicity	
European	59 (26)
Maori	35 (15)
Pacific ^b	36 (16)
Asian ^c	71 (31)
Other	25 (11)
Education^a	
Did not complete secondary	23 (10)
Secondary	31 (14)
Tertiary	170 (75)
Smokers in household	
0	145 (64)
1	46 (20)
≥2	35 (15)
Household size	
1–2	26 (12)
3–4	91 (40)
5–9	98 (43)
≥10	11 (5)

^aOf mother for enrolled children. ^bIncludes Samoan (n = 16), Tongan (n = 7), Niuean (n = 5), Cook Islander (n = 5), Tuvalu (2), Fijian (n = 1). ^cIncludes Chinese (n = 16), Indian (n = 29), Fijian Indian (n = 9), Filipino (n = 9), Indonesian (n = 2), Korean (n = 3), Sri Lankan (n = 1), Thai (n = 1), Cambodian (n = 1).

then stored at -20°C . The two samples were stored separately to minimise risks of thawing during handling. Samples were air-freighted in two batches. Serial readings on the waybills recorded that the sample temperature was between -60 to -80°C throughout the transportation period. RSIL reported that all Oracol samples received were of gingival fluid not saliva and were of adequate quality to undergo the specific PT IgG antibody assay.

Data analysis

Descriptive statistics, Cox proportional hazards survival analysis with Kaplan-Meier survival plots, logistic regression were performed using PC-SAS (SAS version 9.2) and a classification analysis was performed using SPAN (Search Partition Analysis Software) SPAN uses Boolean expressions to best partition the data to predict an outcome.¹²

RESULTS

Sample characteristics

Fifteen practices from a range of socioeconomic positions were recruited. Participants were referred predominantly by nurses and receptionists but also by GPs. Of the 303 potential participant referrals, 243 (80%) met study eligibility criteria. Reasons for ineligibility were no longer coughing,

outside the age range, had not presented to the practice, on immunosuppressive therapy, or cough defined as 'normal for them'. Because of the nature of general practice there are likely to be a number of other patients who were potentially eligible (that is, had 2 weeks of cough) who were not invited by practice staff to participate.

Of 243 eligible participants, 226 (93%) were enrolled. Eleven declined and six were unable to be contacted. Study questionnaires were completed by 100%. Oral fluid samples were obtained from 225 (99.5%) [one child was too ill for a sample to be obtained]. Two hundred and sixteen (96%) returned the daily cough checklist, and 90% of required weekly checklists were received (Figure 2).

Seventy (31%) of the 226 participants were children (5–16 years) and 156 (69%) were adults (17–49). Approximately equal proportions of the 70 enrolled children were boys or girls (49% versus 51%). A larger proportion of the 156 enrolled adults were female (female versus male, 69% versus 31%). The sample was ethnically diverse (Table 1). Eighty per cent of adults self-reported previous pertussis vaccination although only 2% could verify the date of their last pertussis vaccine.

Of the 156 adult participants, 22% worked in high contact, at-risk roles for *B. pertussis*

Table 2. Positive oral fluid Pertussis Toxin IgG assay

Study ID	Sex	Age, years months		Sample date	Pertussis IgG titre, AU
Children					
CS105-C	Female	11	3	13-Jun-11	159
CS103-C	Male	11	4	3-Jul-11	83
CS107-C	Male	13	8	3-Jul-11	290
CS121-C	Male	5	9	19-Jul-11	267
CS122-C	Male	15	8	22-Jul-11	86
CS138-C	Female	10	3	29-Jul-11	223
CS142-C	Male	15	11	11-Aug-11	372
CS144-C	Male	14	9	11-Aug-11	90
CS134-C	Male	5	4	23-Aug-11	238
CS148-C	Female	9	0	29-Aug-11	80
CS149-C	Female	5	7	30-Aug-11	131
CS154-C	Female	12	1	1-Sep-11	62 ^a
CS159-C	Male	8	8	20-Sep-11	129
CS173-C	Male	12	6	18-Oct-11	88
CS169-C	Female	9	0	26-Oct-11	84
Adults					
CS001-A	Female	47	6	24-May-11	125
CS015-A	Female	36	6	24-Jun-11	124
CS070-A	Female	39	7	4-Aug-11	600
CS071-A	Male	28	2	4-Aug-11	228
CS084-A	Male	49	10	15-Aug-11	91
CS086-A	Male	19	1	15-Aug-11	81
CS218-A	Female	37	8	6-Sep-11	155
CS242-A	Female	29	10	27-Sep-11	203
CS238-A	Male	37	0	29-Sep-11	75
CS239-A	Male	24	10	4-Oct-11	109
CS249-A	Female	25	4	6-Oct-11	243

^aBorderline result, close to diagnostic threshold. AU = arbitrary unit.

the assay was consistent with recent *B. pertussis* infection with the oral fluid IgG to PT concentration ranging from 75 to 600 AU (Table 2). One result (62 AU) was interpreted as having elevated antibodies close to the diagnostic threshold. Two children with a positive result and the child with the borderline result had received a dose of pertussis vaccine within the previous 12 months, potentially confounding their assay results. Excluding these three, recent *B. pertussis* infection was present in 23 of 223 (10%) including 7% of adults (11/156; five male and six female) and 17% of children (12/66; seven male and five female).

The positive rate in children was higher than in adults, $P = 0.003$. Five children with an elevated PT antibody titre had a symptomatic parent enrolled into the study who returned a negative result. Five of the 11 adults (45%) with *B. pertussis* infection were working or studying in high contact, at risk roles for *B. pertussis* transmission.

Cough duration and pertussis serology

The number of days participants reported coughing could not be shown to differ between those with or without recent *B. pertussis* infection [Cox proportional hazard ratio 1.09, 95% CI = 0.71 to 1.68, $P = 0.68$] (Figure 3).

Symptoms associated with recent *Bordetella pertussis* infection

Analysis of the children's data showed weak evidence for vomiting ($P = 0.08$), but not wheezing ($P = 0.05$), and not headache ($P = 0.07$) to be associated with recent *B. pertussis* infection. In adults no individual symptoms could be shown to be associated with positive oral fluid PT assays.

In adults, the SPAN analysis found the best predictor of pertussis was the combined symptom clusters exercise intolerance, wheezing and vomiting, or exercise intolerance and wheezing but without headache or muscle pain (sensitivity and specificity for predicting recent *B. pertussis* infection were 0.73, positive predictive value (PPV) 0.17, negative predictive value (NPV) 0.97) (Table 3).

For children the best predictor was more complex: presence of vomiting and exercise intolerance but not wheezing or sneezing; or vomiting but not headache; or phlegm but not headache or wheeze; or phlegm and exercise intolerance but not wheeze or sneeze. When all of these symptom clusters were applied to the children's data the sensitivity for predicting recent *B. pertussis* infection was 0.67 and specificity 0.87, PPV 0.53, NPV 0.92 (Table 3).

transmission (11% working with children, 11% in health care) as well as nine students included in the adult sample (6%).

Bordetella pertussis antibody assays

All Oracol samples received by RSIL were of adequate quality to undergo the specific PT IgG antibody assay. For 25 participants

Figure 3. Survival plot of cough duration in study participants with (red) and without (blue) evidence of recent *B. pertussis* infection.




Table 3. Symptom clusters and recent *Bordetella pertussis* infection in adults and children

		Recent <i>Bordetella pertussis</i> infection ^a	
		Yes	No
Adult			
Presence of exercise intolerance, wheezing and vomiting, or exercise intolerance and wheezing but without headache or muscle			
Symptom complex present	Yes	8	39
	No	3	106
Sensitivity = 0.73 (95% CI = 0.43 to 0.90)			
Specificity = 0.73 (95% CI = 0.65 to 0.80)			
Positive predictive value = 0.17 (95% CI = 0.09 to 0.30)			
Negative predictive value = 0.97 (95% CI = 0.92 to 0.99)			
Child			
Presence of vomiting and exercise intolerance but not wheezing or sneezing OR vomiting but not headache OR phlegm but not headache or wheeze OR phlegm and exercise intolerance but not wheeze or sneeze.			
		Recent <i>Bordetella pertussis</i> infection ^a	
		Yes	No
One of these four symptom complexes present	Yes	8	7
	No	4	47
Sensitivity = 0.67 (95% CI = 0.39 to 0.86)			
Specificity = 0.87 (95% CI = 0.76 to 0.94)			
Positive predictive value = 0.53 (95% CI = 0.30 to 0.75)			
Negative predictive value = 0.92 (95% CI = 0.82 to 0.97)			

^aAs defined by an oral fluid IgG antibody titre to PT titre of 70 arbitrary units or more.¹¹

DISCUSSION

Summary

New Zealand is a country with a large infant pertussis disease burden. In the 2000s the New Zealand hospitalisation infant rate (196/100 000)¹³ was threefold higher than contemporary rates in the US (65/100 000),¹⁴ and Australia (56/100 000).¹⁵ The study indicates that *B. pertussis* infection is present in one in 10 individuals aged 5–49 years identified in primary care with acute persistent cough, with a larger proportion of children (17%) than adults (7%). Neither cough duration nor any individual presenting symptom differentiates *B. pertussis* infection from other causes of acute persistent cough.

Strengths and limitations

The study established active surveillance for acute persistent cough in a socioeconomically diverse group of general practices. The study maintained good retention of recruiting practices and a high enrolment and completion rate of patients identified with acute persistent cough. Use of the minimally invasive oral fluid swab

enabled diagnostic testing to be completed on all but one of 226 participants. All oral fluid samples collected were of adequate quality for assay, 100% of enrollees completed the questionnaire and this study achieved high completion rates for the daily (96%) and weekly (90%) cough checklists.

The study was conducted over one winter season, therefore the estimate of the proportion of acute persistent cough that was secondary to *B. pertussis* infection may be lower than that which would have occurred with recruitment over the full calendar year. The seasonality of pertussis is less distinct than that of illnesses caused by respiratory viruses. Epidemic peaks of pertussis have been described in spring and summer (Australia),¹⁶ summer and autumn (The Netherlands)¹⁰ and in winter (Norway, Sweden).¹⁷ Thus by limiting the recruitment period as was done, the study have sampled from a portion of the year when respiratory viruses will have been the predominant infectious cause of acute persistent cough.

Patients could be referred by any member of the practice staff rather than solely the GP. In primary care-based studies of acute

persistent cough that have relied solely on GP identification of cases, conducted as vaccine efficacy trials, a selection bias towards those with an illness more consistent with the classical descriptions of pertussis has been shown to sometimes occur.^{18,19} Thus the recruitment strategy may have yielded a truer estimate of the incidence of *B. pertussis* in those with acute persistent cough than would have been achieved if the study had restricted the enrolment to GP referrals.

Comparison with existing literature

Bordetella pertussis infection was identified less frequently in children in this study than it was in a primary care-based study from Oxfordshire which, using the same diagnostic test, identified pertussis in 37% of children 5–16 years old with acute persistent cough.⁸ Key differences between studies include the recruitment period (Oxfordshire 42 months versus Auckland 6 months), source of referrals (Oxfordshire GP only, Auckland any practice personnel) and differences in the immunisation schedule. In England over most of the time the Oxfordshire study was recruiting (October 2001 to March 2005) the schedule included a primary three dose whole-cell vaccine series alone, with the preschool acellular pertussis vaccine booster introduced only in 2004.²⁰ With the waning of vaccine efficacy (shown to be only approximately 50% 5 years after immunisation with the British whole-cell vaccine) it is to be expected that a larger proportion of school aged children in England would have pertussis than school-aged children in New Zealand where acellular pertussis vaccine booster doses are given at age 4 and 11 years²¹ following a three dose primary infant series.²²

That the school-aged population in New Zealand received more booster vaccinations also explains the more clinically subtle presentation of pertussis in the study. In contrast to the study, longer cough duration, whoop, vomiting, and sputum production all predicted an increased likelihood of *B. pertussis* infection in England.⁸ A lack of difference in cough duration and clinical presentation between those with and without *B. pertussis* infection was recently reported from a French general practice-based survey of adolescents and adults with cough illness.²³ France introduced an adolescent booster dose of pertussis vaccine in 1998 and a cocooning immunisation strategy in 2004.

Implications for research and practice

The frequency with which *B. pertussis*

infection was identified in the study is consistent with frequencies reported in other cough studies of adolescents and adults (12–52%).² *B. pertussis* infection is a frequent cause of acute persistent cough irrespective of whether or not a pertussis outbreak is recognised to be present, hence pertussis should always be included in the differential diagnosis of acute persistent cough.

As the study showed, the clinical presentation is subtle and difficult to distinguish from other causes of acute persistent cough. There is a need for a diagnostic test to enable GPs to differentiate pertussis from other causes of acute persistent cough. The oral fluid-based test used in this study is ideal for the primary care setting given that its sensitivity and specificity were established in this environment, it is non-invasive, and easy to collect. At present though, the assay can be performed only at the RSIL laboratory. There is a need for an assay of this type to be more readily available to GPs.

Twenty-two per cent of the adults with acute persistent cough worked with children or in the health sector. The frequency of *B. pertussis* infection in this subgroup was three times higher than for other adults. This highlights the need both for access to high quality laboratory testing from primary care, and for the consideration of other immunisation strategies such as cocooning for population subgroups more likely to come in contact with young infants.²⁴

The oral fluid assay creates the potential for the understanding of pertussis epidemiology to increase. Substantial under reporting of pertussis has been recognised for many decades and is one of the defining features of pertussis epidemiology.²⁵ The availability of a diagnostic test which is non-invasive and has adequate sensitivity and specificity facilitates population-based studies of pertussis epidemiology that are less likely to be compromised by poor response rates or highly selected patient populations.

B. pertussis is a common cause of acute persistent cough in New Zealand school-aged children and younger adults identified in primary care with acute persistent cough. In populations that have received booster immunisations, pertussis is difficult to distinguish clinically from other causes of acute persistent cough. An oral fluid-based assay is an ideal test for primary care settings and efforts should be made to make this test widely available. This would improve diagnosis and aid on-going refinement of pertussis immunisation policy.

Funding

This study was funded by GlaxoKlineSmith New Zealand Ltd (30242). However the funder played no part in the research design, analyses and reported findings of this study. The study funding covered all test costs. GSK was not involved in any way in our decision to use the oral fluid assay, nor arrangements we used to collect samples, have them processed in New Zealand and transported to London for the assay to take place.

Ethical approval

Granted by the Northern Regional X Ethics Committee, 18th January 2011 (NTX/10/12/122).

Provenance

Freely submitted; externally peer reviewed.

Competing interests

The authors have declared no competing interests.

Acknowledgements

We would like to thank the patients who participated in this study, and the general practices involved, and in particular the reception staff who were instrumental in screening most of the participant eligibility and recruitment. Thanks also to staff at LabPLUS ADHB for their management of the oral fluid samples.

Discuss this article

Contribute and read comments about this article on the Discussion Forum: <http://www.rcgp.org.uk/bjgp-discuss>

REFERENCES

1. McIntyre P, Wood N. Pertussis in early infancy: disease burden and preventive strategies. *Curr Opin Infect Dis* 2009; **22(3)**: 215–223.
2. Cherry JD. The epidemiology of pertussis: a comparison of the epidemiology of the disease pertussis with the epidemiology of Bordetella pertussis infection. *Pediatrics* 2005; **115(5)**: 1422–1427.
3. de Melker HE, Versteegh FG, Conyn-Van Spaendonck MA, *et al*. Specificity and sensitivity of high levels of immunoglobulin G antibodies against pertussis toxin in a single serum sample for diagnosis of infection with Bordetella pertussis. *J Clin Microbiol* 2000; **38(2)**: 800–806.
4. Diez-Domingo J, Ballester A, Baldó JM, *et al*. Incidence of pertussis in persons < or =15 years of age in Valencia, Spain: seroprevalence of antibodies to pertussis toxin (PT) in children, adolescents and adults. *J Infect* 2004; **49(3)**: 242–247.
5. Nennig ME, Shinefield HR, Edwards KM, *et al*. Prevalence and incidence of adult pertussis in an urban population. *JAMA* 1996; **275(21)**: 1672–1674.
6. Wright SW, Edwards KM, Decker MD, Zeldin MH. Pertussis infection in adults with persistent cough. *JAMA* 1995; **273(13)**: 1044–1046.
7. Lasserre A, Laurent E, Turbelin C, *et al*. Pertussis incidence among adolescents and adults surveyed in general practices in the Paris area, France, May 2008 to March 2009. *Euro Surveill* 2011; **16(5)**. pii: 19783.
8. Harnden A, Grant C, Harrison T, *et al*. Whooping cough in school age children with persistent cough: prospective cohort study in primary care. *BMJ* 2006; **333(7560)**: 174–177.
9. Gilberg S, Njamkepo E, Du Châtelet IP, *et al*. Evidence of Bordetella pertussis infection in adults presenting with persistent cough in a french area with very high whole-cell vaccine coverage. *J Infect Dis* 2002; **186(3)**: 415–418.
10. de Melker HE, Schellekens JF, Neppelenbroek SE, *et al*. Reemergence of pertussis in the highly vaccinated population of the Netherlands: observations on surveillance data. *Emerg Infect Dis* 2000; **6(4)**: 348–357.
11. Litt DJ, Samuel D, Duncan J, *et al*. Detection of anti-pertussis toxin IgG in oral fluids for use in diagnosis and surveillance of Bordetella pertussis infection in children and young adults. *J Med Microbiol* 2006; **55(Pt 9)**: 1223–1228.
12. Marshall RJ. Partitioning methods for classification and decision making in medicine. *Stat Med* 1986; **5(5)**: 517–526.
13. Grant C. Recent indication of progress in pertussis hospitalisation rates in NZ. *Aust NZ J Pub Health* 2012; **36(4)**: 398.
14. Cortese MM, Baughman AL, Zhang R, *et al*. Pertussis hospitalizations among infants in the United States, 1993 to 2004. *Pediatrics* 2008; **121(3)**: 484–492.
15. Elliott E, McIntyre P, Ridley G, *et al*. National study of infants hospitalized with pertussis in the acellular vaccine era. *Pediatr Infect Dis J* 2004; **23(3)**: 246–252.
16. Andrews R, Herceg A, Roberts C. Pertussis notifications in Australia, 1991 to 1997. *Commun Dis Intell* 1997; **21(11)**: 145–148.
17. Lindgren C, Milerad J, Lagercrantz H. Sudden infant death and prevalence of whooping cough in the Swedish and Norwegian communities. *Eur J Pediatr* 1997; **156(5)**: 405–409.
18. Cherry JD, Heininger U, Stehr K, Christenson P. The effect of investigator compliance (observer bias) on calculated efficacy in a pertussis vaccine trial. *Pediatrics* 1998; **102(4 Pt 1)**: 909–912.
19. Stehr K, Cherry JD, Heininger U, *et al*. A comparative efficacy trial in Germany in infants who received either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP vaccine, or DT vaccine. *Pediatrics* 1998; **101(1 Pt 1)**: 1–11.
20. Health Protection Agency. *Vaccine policy developments. Developments in vaccine policy and practice from 1990*. London: Health Protection Agency, 2012.
21. Jenkinson D. Duration of effectiveness of pertussis vaccine: evidence from a 10 year community study. *Br Med J (Clin Res Ed)* 1988; **296(6622)**: 612–614.
22. Ministry of Health. *Immunisation handbook 2011*. Wellington: Ministry of Health, 2011.
23. Lasserre A, Laurent E, Turbelin C, *et al*. Pertussis incidence among adolescents and adults surveyed in general practices in the Paris area, France, May 2008 to March 2009. *Euro Surveill* 2011 Feb 3; **16(5)**. pii: 19783.
24. Forsyth KD, Wirsing von Konig C-H, Tan T, *et al*. Prevention of pertussis: recommendations derived from the second Global Pertussis Initiative roundtable meeting. *Vaccine* 2007; **25(14)**: 2634–2642.
25. Grant CC, Cherry JD. Keeping pace with the elusive Bordetella pertussis. *J Infect* 2002; **44(1)**: 7–12.